Choice of LC-MS Methods for the Absolute Quantification of Drug-metabolizing Enzymes and Transporters in Human Tissue: a Comparative Cost Analysis
Overview
Affiliations
The quantification of drug-metabolizing enzymes and transporters is important for in vitro-in vivo extrapolation (IVIVE) of xenobiotic clearance, which has become an integral part of drug development. There are different mass spectrometry-based techniques used for quantitative proteomics, and as more laboratories are opting for the use of these methods, selecting the most appropriate tool is becoming a concern. For the first time, we attempt to determine the significance of cost of different LC-MS methods of quantitative analysis of these proteins and to present a framework to objectively assess the choice of the techniques. Based on our analysis, quantification using labeled internal standards is more expensive per sample but provides higher quality data than label-free quantification. Quantification using absolute quantification synthetic peptides is the approach of choice for analyzing less than nine proteins, whereas when quantifying a defined set of proteins (10-50), such as enzymes, in a reasonably large number of samples (20-100), the quantification concatemer technique is more economical, followed by label-free quantification. When analyzing proteomes or sub-proteomes (≥500 proteins), label-free quantification is more cost-effective than the use of labeled internal standards. A cost-benefit approach is described to assess the choice of the most appropriate mass spectrometry-based approach for the quantification of proteins relevant to IVIVE.
Wang X, Shi J, Zhu H Methods Mol Biol. 2022; 2603:269-283.
PMID: 36370287 DOI: 10.1007/978-1-0716-2863-8_22.
Ahire D, Basit A, Karasu M, Prasad B J Pharm Sci. 2021; 110(7):2833-2840.
PMID: 33785352 PMC: 8772585. DOI: 10.1016/j.xphs.2021.03.020.
Quantification of Proteins Involved in Intestinal Epithelial Handling of Xenobiotics.
Al-Majdoub Z, Couto N, Achour B, Harwood M, Carlson G, Warhurst G Clin Pharmacol Ther. 2020; 109(4):1136-1146.
PMID: 33113152 PMC: 8048492. DOI: 10.1002/cpt.2097.
Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes.
Jamwal R, Barlock B Pharmaceuticals (Basel). 2020; 13(9).
PMID: 32872474 PMC: 7560175. DOI: 10.3390/ph13090222.
Assessment of the Interaction Potential of (L.) Extracts on CYP2B6, 3A4, and Rifampicin Metabolism.
Kumar S, Bouic P, Rosenkranz B Front Pharmacol. 2020; 11:517.
PMID: 32425779 PMC: 7204527. DOI: 10.3389/fphar.2020.00517.